BMS-587101

• Description:

  BMS-587101 is a potent and orally active antagonist of leukocyte function associated antigen-1 (LFA-1) . BMS-587101 has anti-inflammatory effects and can be used for rheumatoid arthritis research[1][2].

• UNSPSC:

  12352005

• Target:

  Integrin

• Type:

  Reference compound

• Related Pathways:

  Cytoskeleton

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/bms-587101.html

• Purity:

  99.39

• Solubility:

  DMSO : 260 mg/mL (ultrasonic)

• Smiles:

  O=C(C1=CSC(CN(C[C@H]2C3=CC=C(C#N)C=C3)C[C@]2(N(C)C(N4C5=CC(Cl)=CC(Cl)=C5)=O)C4=O)=C1)O

• Molecular Formula:

  C26H20Cl2N4O4S

• Molecular Weight:

  555.43

• References & Citations:

  [1]Dominique Potin, et al. Discovery and development of 5-[ (5S,9R) -9- (4-cyanophenyl) -3- (3,5-dichlorophenyl) -1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-yl-methyl]-3-thiophenecarboxylic acid (BMS-587101) --a small molecule antagonist of leukocyte function associated antigen-1. J Med Chem. 2006 Nov 30;49 (24) :6946-9.|[2]Suzanne J Suchard, et al. An LFA-1 (alphaLbeta2) small-molecule antagonist reduces inflammation and joint destruction in murine models of arthritis. J Immunol. 2010 Apr 1;184 (7) :3917-26.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 2

• CAS Number:

  [509083-77-6]